In a commendable effort, Merck & Co has managed to get a green signal from the US health regulators for a joint pill for all those who are suffering with health concerns of diabetes and high cholesterol.

While the news is getting the much deserved attention from medical fraternity across the world, it’s being believed that Juvisync would become a sure shot hit in the market and sales figures would be worth appreciating.

It’s being claimed that the pill would have same effects of that being obtained from drug maker’s diabetes medicine Januvia, along with simvastatin.

If reports are to be believed, nearly 20 million Americans are battling with type 2 diabetes and a significant proportion of them are told to have high cholesterol levels. The unique feature of catering to the dual health issues is the unique selling point of the drug and if experts are to be believed, it could prove out to be an inflection point in the history of the drug maker.

It has been claimed by Merck's Vice President for diabetes and endocrinology, Dr. Barry Goldstein that nearly 40% of the diabetic patients with heart concerns are struggling to get hold of statin treatment, which makes the combined pill a major breakthrough.

With the news hitting the contours of the market, the shares of Merck jumped by 3% to $31.79 in late-afternoon trading.